With the intention of achieving improved palliation and improved survival, we have devised a regimen which aims to produce rapid remission induction with a high response rate and acceptable toxicity, while at the same time withholding alkylating agents for use in a high-dose intensification phase at the time of best conventional response. We chose the combination of weekly bolus doxorubicin and continuous infusional 5-fluorouracil (AcF). There has been interest recently in scheduling alterations of these agents in an attempt to produce improved response rates and increased dose AUCs while minimising acute toxicities, i.e. attempting to enhance the therapeutic index of these agents (Hansen et al., 1987; Twelves et al., 1991) .
Weekly doxorubicin does not appear to compromise response rates in comparison to a 3 weekly schedule of the same total dose (Richards et al., 1992) . Impaired liver function sometimes necessitates dose reduction of anthracyclines when used at conventionally 'maximum' doses. This problem can be circumvented by weekly therapy involving a similar or increased total anthracycline dose intensity but with lower peak plasma levels (Twelves et al., 1989) .
We therefore designed a non-randomised single arm (phase II) study incorporating doxorubicin dose escalation to investigate this regimen in patients with aggressive locoregional relapse and/or visceral metastatic disease. The primary end point for our study was response rate after at least 6 weekly cycles of AcF. We also report here toxicity, survival and disease progression data.
Patients and methods Patient population Approval for this study was obtained from the local medical ethics committee. Informed consent was obtained before commencement of treatment. Patients included had to be 60 years of age or less with a microscopically confirmed diagnosis of breast carcinoma, either loco-regionally recurrent or metastatic.
Disease present was required to be bi-dimensionally measurable. Performance status (ECOG) was required to be 3 or less. All patients had to be off all chemotherapy for at least 3 weeks (6 weeks in the case of mitomycin-C), have recovered from the toxic effects of previous chemotherapy and white cell count (WCC)> 3 x 1091 1-, platelets) 100 x 1091 -'. Pretreatment cardiac ejection fractions were mandatory and patients were excluded if they had any past history of cardiac disease or a cardiac ejection fraction less than 30%.
Treatment regimen
The treatment regimen consisted of continuous infusional 5-fluorouracil with weekly bolus doxorubicin (AcF). 5-FU at a constantly infused dose of 200 mg m-2 day-' was given via a Hickman line using a continuous ambulatory drug delivery pump (Pharmacia 'CADD' or Medex 'Walkmed'). al., 1977, 1978) . Toxicity was assessed by WHO toxicity criteria weekly. Patients continued to be seen 6 weekly after completion of therapy. Selected patients who had an objective response by UICC criteria (responses confirmed by two measurements at least four weeks apart) were considered for high-dose therapy with peripheral blood stem cell (PBSC) support. Patients routinely discontinued AcF treatment at 12 weeks if disease progression had occurred or if they had had 3 consecutive weeks off therapy because of toxicity.
Statistical methods
Fisher's exact test was used to compare groups for response and toxicity. Survival of the cohort and its subgroups was analysed by the Kaplan-Meier/log-rank method.
Results

Patient population
Fifty-six patients with metastatic and locally recurrent breast cancer were entered over a period of 34 months between February 1992 and December 1994 (mean age 43.4 years, range 26-57 years). Fifty-four patients were assessable for response. One patient had early grade 4 mucositis 3 weeks into therapy. This patient was included in the dose intensity, toxicity and survival analysis, but was excluded from the response analysis. Another patient had essential information missing and was excluded (Table I) .
Of the 56 patients, 45 (80%) had metastatic disease, and 79% of patients had visceral metastases. Eleven patients (20%) had loco-regional recurrence as their only site of disease. Sites of metastases are described in Table I . The two patients with brain metastases (who also had multiple visceral sites of disease) additionally received whole-brain palliative radiotherapy. All but one of those with bone metastases had evaluable disease at other sites. This patient had a large destructive symptomatic bi-dimensionally measurable sternal metastasis extending into the adjacent soft tissue.
Median performance status of all patients was 1 (WHO criteria) with a range of 0-3. Patients received a median of 11 cycles of AcF (range 3 -19) (see Table I ).
Previous therapy Twenty-one patients (38%) had received previous cytotoxic chemotherapy. Of those who had had previous chemotherapy, only 2 patients had had more than one previous course. Ten patients had received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy, and four had received other adjuvant regimens. Six had received a previous course of CMF for relapsed disease, but only five patients (13%) had previously received an anthracycline. In contrast, all but one of those previously receiving chemotherapy had bolus fluorouracil as part of adjuvant or nonadjuvant treatment.
Intended and delivered chemotherapy doses All patients were planned to receive continuous 5-FU 200 mg m-2 day-' (dose intensity (DI)= 1400 mg m-2 week-'). The mean actual 5-FU dose delivered was 176 mg m-2 day-' (DI= 1274 mg m-2 week-') (see Table  II ). Initially, we were cautious in prescribing doxorubicin; the first 13 patients including five with impaired liver function were prescribed 20 mg m-2 weekly (one of these 13 had early (Table  II) . Because of the difficulty in delivering 30 mg m-2 week-', the last 13 patients enrolled at an intended dose of 25 mg m-2 week-'. The 25 mg m-2 week-' intended dose level cohorts are grouped together in Table II (n=22). The mean intended dose for the entire patient cohort was 25.6 mg m-2 weekly. The mean delivered doxorubicin dose intensity resulting from delays or reductions was 18.7 mg m-2 week-'. The mean doxorubicin dose intensity delivered to first documentation of partial response was 21.6 mg m-2 week-'. The given doxorubicin dose intensities within the intended dose increment cohorts are shown in Table II A median of 6 weeks therapy was required for patients to achieve PR, and the median time to best response was 11 weeks (range 5-17 weeks).
The responses noted were typically rapid with 68% of partial responses seen by 6 weeks and 88% of responses seen by 7 weeks. In many patients symptomatic and objective responses were seen by the second week, ahead of any clinically detectable toxicity. Toxicity As expected, the major toxicities of this regimen were mucositis, neutropenia, alopecia and the palmar -plantar syndrome (Table IV) . There were 11 episodes (19%) of Hickman line complications (thrombosis, sepsis, line falling out) but no treatment-related deaths.
Fisher's exact test was used to compare toxicity for intended doxorubicin dose intensities at the three levels of 20 mg m-2 week-', 25 mg m-2 week -' and 30 mg m-2 week-'. Those allocated to a planned dose of > 25 mg m-2 week-' doxorubicin suffered significantly more grade 3 + mucositis (P= 0.04) compared with those with a planned dose intensity of 25 mg m-2 week-'.
Progression and survival Thirty patients within the AcF group went on to receive PBSC-rescued high-dose therapy. These patients probably skew the progression-free and survival data. We have therefore not included Kaplan-Meier survival curves as they are not representative of the study regimen.
Median follow-up of the group is 18.5 months (range 9-38 months). Median overall survival of the whole group was 13 months and that of patients with visceral metastases 12 months. Those without evidence of visceral disease at entry did significantly better (P=0.037). Median time to progression for the whole group was 10 months. Progression-free survival for those without visceral metastases was also significantly longer (P=0.031).
Discussion
Several studies have suggested independent improvements in the therapeutic index of both 5-FU in breast (Hansen et al., 1987; Gordon et al., 1990) and colonic (Lokich et al., 1989) cancer; and of anthracyclines in breast cancer (Gordon et al., 1990 ) and non-small-cell lung cancer (Valdivieso et al., 1984) using frequent low-dose scheduling. Other studies in breast cancer have shown equal efficacy and toxicity of low dose weekly anthracyclines compared with the three weekly regimens but demonstrated worsened quality of life for the weekly regimen (Twelves et al., 1991; Richards et al., 1992) . The AcF regimen has potential, through alterations of schedule, to improve the therapeutic indices of both 5-FU and doxorubicin. The data demonstrate that this regimen induces rapid remissions with a 20% CR rate, yet retains a tolerable toxicity profile. The CR rate for visceral metastases with AcF is similar to the aggressive Duke AFM remission induction regimen (achieved in 19% of their patients) (Jones et al., 1990) . Smith and Powles, 1991.) Longer-term adverse effects such as cardiotoxicity may be reduced by alteration in the scheduling of anthracyclines (Torti et al., 1983; Valdivieso et al., 1984; Weiss and Manthel, 1980) , and we felt that this was important as the probability of cyclophosphamide-induced cardiotoxicity is increased by prior doxorubicin therapy (Gottdiener et al., 1981) . (Cyclophosphamide is used in the PBSC recruitment phase of our programme.)
The concepts of dose intensity and dose scheduling cannot currently be unified into one theory for tumour response (Hryniuk, 1988; Hryniuk and Brush, 1984) . It is possible that there is an improvement in the therapeutic index of this regimen as a result of scheduling changes of these drugs. This may be due to increased dose intensity as a result of modified organ toxicity, but further studies are required to define this. Dose intensity analysis suggests that the relative dose intensities of 5-FU and doxorubicin in AcF compare favourably with other doxorubicin and 5-FU-containing regimens (Table V) .
Toxicities with this regimen are acceptable and the most troublesome of these, mucositis, was tolerated surprisingly well with an active prophylactic approach to mouth care.
In the absence of any clinical difference in response between the 25 and 30 mg m-2 week-' doxorubicin doses and in view of a relationship between higher doxorubicin dose intensity and grade 3 mucositis, we have now adopted a dose of 25 mg m-2 week-' as being optimally tolerable and effective. Given the small subgroup numbers and the tight relative dose intensity range, it is not surprising that we failed to demonstrate a relationship between doxorubicin dose intensity and any of the outcome or toxicity parameters (apart from mucositis).
As this regimen was developed specifically for remission induction before high-dose therapy, some comments about the timing of the latter are pertinent. If response to conventional chemotherapy serves as a marker of optimal selection for intensification, then this is probably after the seventh cycle when 88% of responding patients should have achieved a partial response. If, however, maximal debulking is felt to be important, then the optimal timing of high-dose therapy lies between the tenth and twelfth cycle.
In our programme patients who achieve CR or definite PR are considered for the high-dose therapy/PBSC-rescue arm of the programme. It will therefore be difficult to assess the contribution of AcF to overall survival of this bestresponding subgroup of patients, and removal of this group from the cohort would, of course, skew the survival data towards the poorly responding patients. The survival of patients with visceral metastases appears to be much better than expected compared with our own unpublished and published (Gregory et al., 1993) historical controls (12.5 vs 7 or 4.5 months) and may therefore be related to the high-dose therapy component of the programme, but longer follow-up is clearly required for these patients. We believe that use of this induction regimen allows the majority of patients with poor-prognosis advanced breast cancer to achieve valuable palliative responses with tolerable toxicity and impressive debulking, which are justifiable aims in themselves. In addition, this regimen permits patients the option of entry into high-dose therapy studies.
